title: Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
abstract: Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p < .0001), male sex (p = .01), valvular heart disease (p = .001), and hypertension (p = .04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p < .0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.
authors.affiliation: a Division of Hematology , Mayo Clinic , Rochester , MN , USA.
authors.forename: Tait D
authors.initials: TD
authors.lastname: Shanafelt
authors.affiliation: a Division of Hematology , Mayo Clinic , Rochester , MN , USA.
authors.forename: Sameer A
authors.initials: SA
authors.lastname: Parikh
authors.affiliation: b Division of Cardiovascular Diseases , Mayo Clinic , Rochester , MN , USA.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Noseworthy
authors.affiliation: c Department I of Internal Medicine , Center of Integrated Oncology, University of Cologne , Cologne , Germany.
authors.forename: Valentin
authors.initials: V
authors.lastname: Goede
authors.affiliation: d Research Comp Genomics , Mayo Clinic , Rochester , MN , USA.
authors.forename: Kari G
authors.initials: KG
authors.lastname: Chaffee
authors.affiliation: e Department I of Internal Medicine , Centre for Integrated Oncology, University Hospital Cologne , Cologne , Germany.
authors.forename: Jasmin
authors.initials: J
authors.lastname: Bahlo
authors.affiliation: f Department of Hematology and Internal Oncology , University of Cologne , Cologne , Germany.
authors.forename: Timothy G
authors.initials: TG
authors.lastname: Call
authors.affiliation: f Department of Hematology and Internal Oncology , University of Cologne , Cologne , Germany.
authors.forename: Susan M
authors.initials: SM
authors.lastname: Schwager
authors.affiliation: f Department of Hematology and Internal Oncology , University of Cologne , Cologne , Germany.
authors.forename: Wei
authors.initials: W
authors.lastname: Ding
authors.affiliation: g Department of Internal Medicine and Oncology , University of Cologne , Cologne , Germany.
authors.forename: Barbara
authors.initials: B
authors.lastname: Eichhorst
authors.affiliation: g Department of Internal Medicine and Oncology , University of Cologne , Cologne , Germany.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Fischer
authors.affiliation: h Division of Hematology/Oncology , Mayo Clinic Arizona , , Scottsdale , AZ , USA.
authors.forename: Jose F
authors.initials: JF
authors.lastname: Leis
authors.affiliation: i Division of Medicine , Mayo Clinic , Jacksonville , FL , USA.
authors.forename: Asher Alban
authors.initials: AA
authors.lastname: Chanan-Khan
authors.affiliation: j Department of Internal Medicine , Center of Integrated Oncology, University of Cologne , Cologne , Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
authors.affiliation: k Division of Health Sciences Research , Mayo Clinic , Rochester , MN , USA.
authors.forename: Susan L
authors.initials: SL
authors.lastname: Slager
authors.affiliation: l Division of Hematology , Mayo Clinic , Rochester , MN , USA.
authors.forename: Neil E
authors.initials: NE
authors.lastname: Kay
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology*; D015897:Comorbidity; D005260:Female; D006801:Humans; D015994:Incidence; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010880:Piperidines; D015995:Prevalence; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D055815:Young Adult
chemical_list: D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: Chronic lymphocytic leukemia; atrial fibrillation; ibrutinib; risk factors